期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

白血病干细胞分子生物学特性及其治疗策略研究进展 被引量：3

Molecular characteristics of leukemia stem cells and up-dating therapeutic strategy
下载PDF
导出
摘要 耐药与复发是白血病治疗失败两大主要原因,但其病因与确切分子机制迄今不详。近年来,已有越来越多的研究表明,白血病患者体内除了含有大量幼稚白血病细胞外,还存在着一群比例极少的白血病干细胞(LSCs)。这些肿瘤性干细胞对目前常用的化疗药物无反应,被认为是白血病耐药和复发的主要根源,只有清除LSCs才有可能根治白血病。本文简要介绍白血病干细胞基本分子生物学特性及相应治疗策略研究进展。 Drug resistance and relapse are two major causes for treatment failure of leukemia, but their mechanisms remain elusive. Recently, increasing evidence shows that there is a subset of leukemia stem cells apart from immature leukemia ceils in leukemia patients. These malignant stem ceils do not response to routine chemotherapeutic agents, and may be the source of drug resistance and relapse of leukemia. Permanent cure of leukemia need elimination of these leukemia stem cells. We describe molecular characteristics of leukemia stem cells and possible target therapeutic strategies in this review.
作者 古莹 邱曦 徐荣臻
机构地区 浙江大学医学院附属第二医院血液科
出处 《基础医学与临床》 CSCD 北大核心 2008年第9期904-907,共4页 Basic and Clinical Medicine
基金 国家自然科学基金(30672381)
关键词 白血病干细胞 白血病复发 耐药 leukemia stem cell relapse drug resistance
分类号 R733.7 [医药卫生—肿瘤]
  • 相关文献

参考文献22

  • 1Park CH, Bergsagel DE, McCulloch EA. Mouse myeloma tumor stem cells: a primary cell culture assay [ J ]. J Natl Cancer Inst, 1971,46:411 -422.
  • 2Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell[J]. Nat Med, 1997, 3:730-737.
  • 3Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human a2 cute myeloid leukemia after transplantation into SCID mice[J]. Nature, 1994, 367:645-648.
  • 4Jamieson CH, AiUes LE, Dylla S J, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis[J]. N Engl J Med, 2004, 351:657 -667.
  • 5Ishikawa F, Yoshida S, Saito Y, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region [ J ]. Nat Biotechnol, 2007, 25:1315 - 1321.
  • 6Kelly PN, Dakic A, Adams JM, et al. Tumor growth need not be driven by rare cancer stem cells [ J ]. Science, 2007, 317:337.
  • 7Zhao C, Blum J, Chen A, et al. Loss of beta-Catenin impairs the renewal of normal and CML stem cells in vivo[ J ]. Cancer Cell, 2007, 12:528 - 541.
  • 8Krivtsov AV, Armstrong SA. MLL transloeations, histone modifications and leukaemia stem-cell development [ J ]. Nat Rev Cancer, 2007, 7:823 -833
  • 9van Rhenen A, van Dongen GA, Kelder A, et al. The novel AML stem cell associated antigen CLL-1 aids in discrimina- tion between normal and leukemic stem cells [ J ]. Blood, 2007, 110:2659-2666.
  • 10Stubbs MC, Armstrong SA. Therapeutic implications of leukemia stem cell development [ J ]. Clin Cancer Res, 2007, 13:3439 - 3442.

同被引文献43

  • 1高伟波,陈书长,赵春华.肿瘤干细胞与肿瘤耐药[J].基础医学与临床,2006,26(6):662-667. 被引量：11
  • 2Miyagi T, Wada T, Yamaguchi K. Roles of plasma membrane-associated siatidase NEU3 in human cancers [ J ]. Biochim Biophys Acta, 2008, 1780(3):532-537.
  • 3Kakugawa Y, Wada T, Miyagi T, et al. Up-regulation of plasma membrane-associated ganglioside sialidase (Neu3) in human colon cancer and its involvement in apoptosis suppression[J]. Proc Natl Acad Sci USA, 2002, 99:10718 - 10723.
  • 4Ueno S, Saito S, Miyagi T, et al. Plasma membrane-associated sialidase is up-regulated in renal cell carcinoma and promotes the interleukin-6-induced apoptosis suppression and ceil motility[J]. J Biol Chem, 2006, 281 (12) :7756 - 7764.
  • 5Takara K, Sakaeda T, Okumura K. An update on overcoming MDR1-mediated muhidrug resistance in cancer chemotherapy[J]. Curt Pharm Des, 2006, 12(3) :273 -286.
  • 6Dijkhuis AJ, Douwes J, Kamps W, et al. Differential expression of sphingolipids in P-glycoprotein or multidrug resistance-related protein 1 expressing human neuroblastoma cell lines[J]. FEBS Lett, 2003, 548(1 -3):28 -32.
  • 7Kopitz J, Muhl C, Ehemann V, et al. Effects of cell surface ganglioside sialidase inhibition on growth control and differentiation of human neuroblastoma cells [ J ]. Eur J Cell Biol,1997, 73(1) :1 -9.
  • 8Mauro MJ. Defining and managing imatinib resistance. Hematology Am Soc Hematol Educ Program, 2006, 1 : 219-225.
  • 9Meggyesi N, Kozma A, Halm G, et al. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and Clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients. Acta Haematol, 2012, 127:34-42.
  • 10Leder K, Foo J, Skaggs B, et al. Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia. PLoS One, 2011; 6:e27682.

引证文献3

二级引证文献4

基础医学与临床
2008年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部